brentuximab vedotin

This page shows the latest brentuximab vedotin news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.

Latest news

Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

England’s cost effectiveness watchdog says there are limited treatment options for people who have not responded to, or only have a temporary response to, brentuximab vedotin and cannot have stem
Seattle Genetics claims key US approval for Adcetris

Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Seattle has since turned its attention to its own TNBC
Takeda bags EU approval for Adcetris in lymphoma

CTCL). Adcetris (brentuximab vedotin) - a CD30-targeting antibody drug conjugate (ADC) - already has conditional approval in the EU for certain adult patients with relapsed or refractory CD30-positive Hodgkin lymphoma, but
Seattle Genetics' Adcetris earns FDA priority review status

Adcetris (brentuximab vedotin), an antibody-drug conjugate, was awarded the status based on the results of the phase III ECHELON-1 trial, which had a primary endpoint of an improved PFS
NICE reverses stance on Takeda’s Adcetris

Takeda has claimed a partial win for its non-Hodgkin’s lymphoma drug Adcetris (brentuximab vedotin) after persuading NICE to change its mind and issue new draft guidance. ... I am delighted that patients can maintain long term access to Brentuximab

More from news
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Interview: Trevor Smith, Takeda

Even closer to market is Takeda's monoclonal antibody treatment for Hodgkin's Lymphoma, Adcetris (brentuximab vedotin), which was recommended for European approval in July and which Takeda expects to launch

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director: £48, 000 - £60, 000

Account Manager / Account Director: Competative

Project / Account Manager (Medical Education): Salary TBC

Medical Writers: Competitive Salary and Benefits

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Senior Systematic Review Analyst - Oxford: Negotiable

Account Director: Excellent benefits

Medical Writers Required – Cheshire: DOE

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Medical Writer: Great salary and benefits

Associate Director: £75, 000-90, 000

Consultant Health Economics - London / Oxford: Negotiable

Associate Medical Director: Highly Competitive

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...